Galecto Begins Patient Enrollment In Phase 2 Trial Of Gb1211 In Combo With Atezolizumab To Treat Nsclc
Galecto, Inc., A Clinical Stage Biotechnology Company, Announced That The First Patient Has Been Enrolled In The Phase 2A Gallant-1 Trial (Nct05240131).Gallant-1 Is Designed To Study The Combination Of Gb1211, Galecto
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!